Filters: keyword is Rats [Clear All Filters]
- 2008
Mechanistic model for the acute effect of fluvoxamine on 5-HT and 5-HIAA concentrations in rat frontal cortex,
Eur J Pharm Sci, vol. 33, no. 3, pp. 217-29. DOI
Mechanism-based pharmacodynamic modeling of S(-)-atenolol: estimation of in vivo affinity for the beta1-adrenoceptor with an agonist-antagonist interaction model,
J Pharmacol Exp Ther, vol. 324, no. 3, pp. 1234-42. DOI
- 2007
Allometric scaling of pharmacodynamic responses: application to 5-Ht1A receptor mediated responses from rat to man,
Pharm Res, vol. 24, no. 11, pp. 2031-9. DOI
Pharmacokinetic-pharmacodynamic modeling of the effect of fluvoxamine on p-chloroamphetamine-induced behavior,
Eur J Pharm Sci, vol. 32, no. 3, pp. 200-8. DOI
Pharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of norbuprenorphine in rats,
J Pharmacol Exp Ther, vol. 321, no. 2, pp. 598-607. DOI
Reproducible and time-dependent modification of serum protein binding in Wistar Kyoto rats,
J Pharmacol Toxicol Methods, vol. 56, no. 1, pp. 72-8. DOI
Population pharmacokinetic model of fluvoxamine in rats: utility for application in animal behavioral studies,
Eur J Pharm Sci, vol. 30, no. 1, pp. 45-55. DOI
- 2006
Mechanism-based pharmacokinetic-pharmacodynamic modeling of the respiratory-depressant effect of buprenorphine and fentanyl in rats,
J Pharmacol Exp Ther, vol. 319, no. 2, pp. 682-92. DOI
Correlation between in vitro and in vivo concentration-effect relationships of naproxen in rats and healthy volunteers,
Br J Pharmacol, vol. 148, no. 4, pp. 396-404. DOI
- 2005
Population pharmacokinetic analysis for simultaneous determination of B (max) and K (D) in vivo by positron emission tomography,
Mol Imaging Biol, vol. 7, no. 6, pp. 411-21. DOI
Allometric relationships between the pharmacokinetics of propofol in rats, children and adults,
Br J Clin Pharmacol, vol. 59, no. 6, pp. 705-11. DOI
Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics,
J Pharmacol Exp Ther, vol. 313, no. 3, pp. 1136-49. DOI
High-performance liquid chromatography of nalbuphine, butorphanol and morphine in blood and brain microdialysate samples: application to pharmacokinetic/pharmacodynamic studies in rats,
J Chromatogr B Analyt Technol Biomed Life Sci, vol. 822, no. 1-2, pp. 230-7. DOI
- 2004
Mechanism-based pharmacokinetic-pharmacodynamic modeling of 5-HT1A receptor agonists: estimation of in vivo affinity and intrinsic efficacy on body temperature in rats,
J Pharmacol Exp Ther, vol. 308, no. 3, pp. 1012-20. DOI
- 2003
Anticonvulsant drugs differentially suppress individual ictal signs: a pharmacokinetic/pharmacodynamic analysis in the cortical stimulation model in the rat,
Behav Neurosci, vol. 117, no. 5, pp. 1076-85. DOI
Cyclopentyladenosine and some of its low-efficacy derivatives inhibit striatal synaptosomal release of acetylcholine to a similar degree,
Eur J Pharmacol, vol. 481, no. 2-3, pp. 141-6. DOI
Blood-brain barrier transport of synthetic adenosine A1 receptor agonists in vitro: structure transport relationships,
Eur J Pharm Sci, vol. 20, no. 3, pp. 347-56. DOI
Mechanism-based modeling of the pharmacodynamic interaction of alphaxalone and midazolam in rats,
J Pharmacol Exp Ther, vol. 307, no. 2, pp. 765-75. DOI
Low efficacy adenosine A1 agonists inhibit striatal acetylcholine release in rats improving central selectivity of action,
Neurosci Lett, vol. 343, no. 1, pp. 57-61. DOI
Adenosine A1 receptor agonist N6-cyclopentyladenosine affects the inactivation of acetylcholinesterase in blood and brain by sarin,
J Pharmacol Exp Ther, vol. 304, no. 3, pp. 1307-13. DOI
Dose-dependent EEG effects of zolpidem provide evidence for GABA(A) receptor subtype selectivity in vivo,
J Pharmacol Exp Ther, vol. 304, no. 3, pp. 1251-7. DOI
- 2002
Mechanism-based pharmacokinetic-pharmacodynamic modeling of concentration-dependent hysteresis and biphasic electroencephalogram effects of alphaxalone in rats,
J Pharmacol Exp Ther, vol. 302, no. 3, pp. 1158-67.
Effects of the adenosine A1 receptor allosteric modulators PD 81,723 and LUF 5484 on the striatal acetylcholine release,
Eur J Pharmacol, vol. 454, no. 2-3, pp. 177-82. DOI
Pharmacokinetic-pharmacodynamic modelling of the hypothermic and corticosterone effects of the 5-HT1A receptor agonist flesinoxan,
Eur J Pharmacol, vol. 445, no. 1-2, pp. 43-54. DOI
Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats,
J Pharmacol Exp Ther, vol. 303, no. 3, pp. 1130-7. DOI


